Cipla partners with MNCs to strengthen anti-diabetes innovative portfolio: GlobalData
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
The business and product range of Ipca and that of Unichem complements each others business and product range
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
The burden of treating chronic wounds is growing rapidly due to increasing health care costs
With a focus on optimizing patient experience with next-generation oral dosage forms, the US facility complements the cutting-edge research activities of Roquette’s existing pharma innovation centers in France and Singapore
Showcased digital innovations: MyPKFit, SYNAPSE and Athena at the G20 Health Working Group Meeting
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
This plant adds around 60,000 MT of capacity, scaling Jubilant Ingrevia Limited’s overall annual Acetic Anhydride capacity to 210,000 MT
Digitization has unleashed a flood of data that presents a huge opportunity but is also overwhelming clinicians, nurses, and administrators
Subscribe To Our Newsletter & Stay Updated